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Abstract
Cyclic NGR peptides as homing devices are good candidates for the development of drug conjugates for targeted tumor therapy. In
our previous study we reported that the Dau=Aoa-GFLGK(c[KNGRE]-GG-)-NH2 conjugate has a significant antitumor activity
against both CD13+ HT-1080 human fibrosarcoma and CD13− but integrin positive HT-29 human colon adenocarcinoma cells.
However, it seems that the free ε-amino group of Lys in the cycle is not necessary for the biological activity. Therefore, we de-
veloped novel cyclic NGR peptide–daunomycin conjugates in which Lys was replaced by different amino acids (Ala, Leu, Nle, Pro,
Ser). The exchange of the Lys residue in the cycle simplified the cyclization step and resulted in a higher yield. The new conju-
gates showed lower chemostability against deamidation of Asn than the control compound, thus they had lower selectivity to
CD13+ cells. However, the cellular uptake and cytotoxic effect of Dau=Aoa-GFLGK(c[NleNGRE]-GG-)-NH2 was higher in com-
parison to the control especially on HT-29 cells. Therefore, this conjugate is more suitable for drug targeting with dual targeting
property.
Introduction
Targeted chemotherapy is one of the most promising ap-
proaches for selective cancer treatment that may decrease the
toxic side effects of anticancer drugs. This therapeutic ap-
proach is based on the fact that tumor specific receptors are
highly expressed on cancer cells/tissues. NGR (Asn-Gly-Arg)
motif-containing peptides identified by phage display are suit-
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able candidates for selective drug delivery. NGR peptides bind
to CD13-receptors on tumor cells and tumor related angiogenic
blood vessels [1,2]. CD13 is a transmembrane zinc-dependent
metalloprotease that functions in cell proliferation, cell migra-
tion and angiogenesis [1,3,4]. However, it is known that the
Asn-Gly moiety is subject to Asn deamidation through succin-
imide formation leading to isoaspartic acid (isoAsp, isoD) and
aspartic acid derivatives usually in a ratio of 3:1 after hydroly-
sis [5-11]. IsoDGR peptides are bound to RGD-integrin recep-
tors with high affinity [12-14]. Due to their function in tumor
proliferation, metastasis and angiogenesis, integrin receptors are
also promising targets for cancer therapy. Thus, NGR-peptide
homing devices may provide dual targeted delivery of anti-
cancer drugs.
According to literature data, one of the most stable and tumor-
selective cyclic NGR-peptides is c[KNGRE]-NH2, in which the
α-amino group of the N-terminal Lys is coupled to the
γ-carboxyl group of the glutamic acid residue (head-to-side
chain cycle). In vitro fluorescence microscopy studies of an
Oregon Green (OG) labeled c[KNGRE]-NH2 (OG attached to
the side chain of Lys) revealed selective binding to CD13-re-
ceptor positive (CD13+) HT-1080 human fibrosarcoma cells
and minimal binding to receptor negative (CD13−) MCF-7
human breast adenocarcinoma cells [15]. Moreover, a 68Ga-
radiotracer labeled derivative of the cyclic [KNGRE]-NH2 has
been successfully used for tumor diagnostic studies by PET, in-
dicating its specific binding to CD13 receptor expressing tumor
tissues [16].
Recently, we reported the synthesis and biochemical characteri-
zation of novel cyclic NGR peptides and their corresponding
NGR-drug conjugates. Special attention was paid on the
chemostability and in vitro biological activity of the com-
pounds [17,18]. Daunomycin (Dau) was used as cytotoxic
agent, attached to the NGR-derivatives via oxime linkage. The
prepared conjugates revealed substantial in vitro cytostatic/cyto-
toxic effects. Our results indicated that the conjugates had an
antitumor effect against both CD13+ HT-1080 cells and CD13−
(but integrin receptor positive) HT-29 human colon cancer
cells. Moreover, we showed that the toxicity and the selectivity
of the conjugates highly depended on their structure, cellular
uptake and propensity to deamidation.
The most active conjugate with dual acting properties was
Dau=Aoa-GFLGK(c[KNGRE]-GG-)-NH2 (K, control conju-
gate in this study). In this conjugate the cyclic NGR peptide was
attached through a Gly-Gly dipeptide spacer to the lysine side
chain connected to the chatepsin B labile GFLG spacer that
allows lysosomal drug release. Dau was conjugated to the
GFLG spacer via oxime linkage through an incorporated
aminooxyacetyl (Aoa) moiety. The preparation of the conju-
gate required a sophisticated synthetic route and the use of or-
thogonal protecting groups (Figure 1A). Previous studies indi-
cated that the free ε-amino group of Lys does not have an
impact on the biological activity [15,17]. To prove our assump-
tion, a set of novel cyclic NGR peptide–Dau conjugates were
developed in which the Lys was replaced by different amino
acids (Ala, Leu, Nle, Pro and Ser). The main goal of the present
study was to investigate whether the exchange of the lysine in
the cycle has any influence on the chemostability, selectivity
and antitumor activity of the conjugates.
Here we report on the synthesis and characterization of the
cyclic NGR peptide–Dau bioconjugates including chemosta-
bility, lysosomal degradation, cellular uptake studies and in
vitro cytostatic/cytotoxic effect.
Results and Discussion
Synthesis of cyclic NGR–Dau conjugates
The NGR cyclic peptides were prepared as shown in Figure 1.
All derivatives were synthesized by SPPS on a Rink-Amide
MBHA Resin, using Fmoc/t-Bu strategy. The anticancer drug
daunomycin was conjugated to the Aoa-GFLGK spacer via
oxime linkage [17]. This spacer is degraded by lysosomal en-
zymes ensuring the release of the Dau=Aoa-Gly-OH as the
smallest bioactive metabolite in lysosomes [19]. It is well
known from our previous studies that not only the free Dau but
also Dau containing metabolites like Dau=Aoa-Gly-OH bind to
DNA efficiently resulting in antitumor activity. The exchange
of the Lys in the cycle simplified the cyclization step and due to
the avoidance of the Fmoc cleavage in solution (Figure 1B vs
1A) the compounds could be obtained in higher yields com-
pared to the control (K). Isopropylidene protected aminooxy-
acetyl moiety was used to avoid unwanted reactions with alde-
hydes or ketones. This protecting group was removed with 1 M
methoxylamine in 0.2 M NH4OAc solution (pH 5.0) prior to the
Dau conjugation. The final cyclic NGR peptide–Dau conju-
gates were characterized by analytical HPLC and mass spec-
trometry (Table 1, Supporting Information File 1), whereby the
purity was over 95% in all cases. In comparison with the control
conjugate (K) significantly higher overall yield was observed in
the case of conjugates 2, 3 and 4 obtained with a lower yield.
The improvement was observed especially in the cyclization
step that might be explained by the lack of bulky protecting
groups on amino acids used instead of Lys.
Chemostability of cyclic NGR peptide–dauno-
mycin conjugates
The chemostability of cyclic NGR peptide–drug conjugates was
studied under the treatment conditions used for the in vitro cyto-
toxicity experiments. Samples were taken at 0 min, 6 h and
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Figure 1: Schematic synthesis of cyclic KNGRE (A) and XNGRE (B) drug conjugates. a) Mtt-cleavage: 2% TFA/DCM; b) Fmoc-Aaa(X)-OH coupling;
c) Fmoc-cleavage 2% piperidine/2% DBU/DMF, 0.1 M HOBt; d) cleavage from resin 2.5% TIS/2.5% H2O/95% TFA (rt, 3 h); e) salt exchange Pyr·HCl
10 equiv/MeOH (1 h); f) cyclization: BOP 3 equiv/HOBt 3 equiv/DIPEA 6 equiv/DMF (c = 0.5 mg/mL, rt, 24 h); g) deprotection of aminooxyacetic acid
0.2 M NH4OAc solution (pH 5.0)/1 M methoxylamine (rt, 1 h); h) daunomycin conjugation (rt, 24 h) in 0.2 M NH4OAc solution (pH 5.0); i) Fmoc-
cleavage 4% hydrazine/DMF (rt, 2 h).







1 Dau=Aoa-GFLGK(c[CONH-ANGRE]-GG)-NH2 2.2 22.2 1725.8/1725.8
2 Dau=Aoa-GFLGK(c[CONH-LNGRE]-GG)-NH2 7.0 22.4 1767.8/1767.4
3 Dau=Aoa-GFLGK(c[CONH-NleNGRE]-GG)-NH2 10.6 22.6 1767.8/1767.2
4 Dau=Aoa-GFLGK(c[CONH-PNGRE]-GG)-NH2 6.2 17.3 1751.1/1751.4
5 Dau=Aoa-GFLGK(c[CONH-SNGRE]-GG)-NH2 1.8 20.1 1741.9/1741.7
K Dau=Aoa-GFLGK(c[CONH-KNGRE]-GG)-NH2 2.0 23.0 1783.6/1783.0
aThe overall yield was calculated for the starting amount and capacity of the resin. bHPLC: KNAUER 2501; column: Phenomenex Luna C18
(250 mm × 4.6 mm, 5 µm silica, 100 Å pore size; gradient: 0 min 0% B; 5 min 0% B; 50 min 90% B; eluents: A) 0.1% TFA/water, B) 0.1% TFA/MeCN-
H2O (80:20, v/v); flow rate: 1 mL/min; detection: λ = 220 nm. cESIMS: Bruker Daltonics Esquire 3000+ ion trap mass spectrometer; spectra were
acquired in the 50–2500 m/z range.
72 h. The deamidation rate was evaluated by HPLC–MS. In
contrast to the control conjugate (K) that showed high stability
in our previous study, the new conjugates rearranged in time.
The results showed very similar isoAsp/Asp (≈3:1) rates after
deamidation of conjugates 1, 2, 3, and 5 calculated from the
area under the curve (Table 2, Supporting Information File 1,
Figures S1–S5). After 6 h, moderate rearrangement was ob-
served which increased in time. However, 54–58% of the parent
cyclic NGR conjugates were still intact after 72 h. Lower
stability was observed in the case of the Pro-containing conju-
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Table 2: Chemostability of cyclic NGR peptide-Daunomycin conjugates.
Ratio of Asn-/Asp-/isoAsp-derivatives
(DMEM CM, 37 °C)
Code AAA in position X of the conjugates 6 h 72 h
NGR DGR isoDGR NGR DGR isoDGR
1 Ala 96 0 4 58 11 31
2 Leu 93 0 7 54 11 35
3 Nle 93 1 6 58 9 33
4 Pro 73 14 13 19 46 35
5 Ser 93 0 7 56 12 31
K Lys 100 0 0 100 0 0
Table 3: In vitro cytostatic/cytotoxic effects of compounds on HT-29 and HT-1080 cells.








Daunomycin 1.4 ± 0.6 0.3 ± 0.2 0.5 ± 0.2 0.1 ± 0.1
Dau=Aoa-GFLGK(c[KNGRE]-GG)-NH2 (K) 5.7 ± 0.5 8.7 ± 1.2 1.4 ± 0.7 3.0 ± 0.6
Dau=Aoa-GFLGK(c[ANGRE]-GG)-NH2 (1) 8.9 ± 0.8 4.3 ± 0.5 3.6 ± 0.7 3.2 ± 0.8
Dau=Aoa-GFLGK(c[LNGRE]-GG)-NH2 (2) 57.5 ± 6.3 47.0 ± 5.4 20.6 ± 0.4 14.1 ± 0.7
Dau=Aoa-GFLGK(c[NleNGRE]-GG)-NH2 (3) 5.5 ± 0.3 2.2 ± 0.2 2.3 ± 0.6 1.3 ± 0.2
Dau=Aoa-GFLGK(c[PNGRE]-GG)-NH2 (4) 9.4 ± 4.0 14.6 ± 4.7 3.5 ±1.0 3.7 ± 0.8
Dau=Aoa-GFLGK(c[SNGRE]-GG)-NH2 (5) >100 64.7 ± 4.9 63.7 ± 9.5 39.4 ± 2.9
gate (4) with faster deamidation and higher ratio of DGR.
Except deamidation no other decomposition could be observed
during this study.
Cytostatic/cytotoxic studies of NGR
peptide–Dau conjugates
Similarly to our previous study the antitumor effects of conju-
gates were examined in vitro on CD13+ HT-1080 human
fibrosarcoma and on CD13− HT-29 human colon adenocarci-
noma cells. Both cell types are integrin receptor positive [17].
The effect of the new drug conjugates was compared with the
toxicity of free Dau and our lead compound Dau=Aoa-
GFLGK(c[KNGRE]-GG)-NH2 (K). The bioconjugates enter
cancer cells most likely by receptor-mediated endocytosis (at
least at lower micromolar concentration) followed by the
release of the active metabolite Dau=Aoa-Gly-OH by lyso-
somal degradation. In contrast, free Dau enters the cells in an
unspecific manner which might explain the lower antitumor
effect of conjugates in comparison with the free drug. In this ex-
periment we measured the cytostatic effect (6 h treatment and
further 66 h incubation after washing out the compounds) and
the cytotoxic effect (72 h treatment). The results are summa-
rized in (Table 3). In contrast to K that is taken up by HT-1080
cells slightly more efficiently than by HT-29 and therefore
shows higher antitumor effect against CD13+ cells, the new
conjugates showed higher cytostatic/cytotoxic effects on the
CD13− HT-29 colon cancer cells. It seems that the replacement
of Lys by the hydrophilic amino acid Ser is not favorite. How-
ever, the incorporation of hydrophobic amino acids was well
accepted. The conjugate with bulky side chain in this position
(Leu) had higher IC50 values that might be explained by ster-
ical hindrance. The conjugates with Ala or Nle showed the best
antitumor activity on both cell lines. The Nle containing conju-
gate presented similar activity on HT-1080 and higher activity
on HT-29 cells compared to the control conjugate. It is worth
mentioning that Nle has a linear hydrocarbon side chain with
the same length as Lys, the amino functional group missing. To
further characterize the biological activity of the conjugates,
their lysosomal degradation and cellular uptake were studied.
In this study our goal was to compare the in vitro antitumor ac-
tivity of the conjugates. We believe that the measurement of
binding affinity on isolated receptors, that was not task of this
experiment, could not explain properly the efficacies and selec-
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915
Figure 2: (A) HT1080 and (B) HT-29 cells. Uptake of conjugate 1 (light green); 2 (red); 3 (light blue); 4 (pink); 5 (green); K (yellow). Empty control with
purple color.
tivity. The receptor profile of both cell types are very complex.
HT-1080 contain different integrins (RGD, collagen, etc) next
to CD13 receptor [20]. HT-29 expresses all the known β1 RGD
dependent receptors furthermore αvβ3, αvβ5, αvβ6, αvβ8 [21].
Most of the mentioned integrins bind isoDGR peptides with dif-
ferent affinity from nM up to μM concentration that depends on
the structure of the peptide [2]. In addition the binding affinity
of the different integrins is not consequent to the peptides.
Furthermore, there are only a few binding affinity studies for
CD13 suggesting several hundred nM IC50 values for NGR
peptide derivatives [22]. The biological activity of NGR and
isoDGR peptides might be influenced also by the density of the
different receptors on the tumor cells, which is not so easy to
identify in case of such complex receptor profile. Therefore, the
resulted amount of isoDGR derivatives might provide similar
activity both on CD13+ and CD13− cells.
Lysosomal degradation
Lysosomal degradation studies were carried out as previously
described [17]. The results showed that all conjugates decom-
posed within 6 h (Supporting Information File 1, Figures
S6–S10). The main cleavage site of the conjugates could be
detected between Gly-Phe within the enzyme labile spacer re-
sulting in the smallest active Dau containing metabolite
Dau=Aoa-Gly-OH. No significant difference in degradation
speed of the conjugates was observed. Therefore, the replace-
ment of Lys has no influence on the biological activity through
the lysosomal degradation.
Cellular uptake
Daunomycin is fluorescent therefore the cellular uptake of Dau
containing conjugates can be followed by flow cytometry
(Figure 2). The new conjugates were taken up by HT-29 cells in
a higher amount than by HT-1080 cells. Conjugates 2, 3 and 4
showed significantly higher accumulation in HT-29 than in
HT-1080 cells compared to the other conjugates. The highest
uptake by both cell types was observed in the case of conju-
gates 3 and 4. The low cytostatic/cytotoxic effects of conjugate
5 can be explained by the results of cellular uptake study. The
Ser-containing conjugate did not enter HT-1080 cells, while a
slightly higher cellular uptake was detected in HT-29 cells, al-
though this uptake was still much lower than in the case of the
other conjugates.
Conclusion
From this study we can conclude that replacement of Lys in the
Dau=Aoa-GFLGK(c[KNGRE]-GG)-NH2 conjugate by differ-
ent amino acids provides a more convenient and cost-effective
synthetic route resulting in a higher yield, which might be rele-
vant for larger scale synthesis needed for further in vivo studies.
We show that the changes decrease the chemostability of the
cyclic NGR moiety, resulting in the formation of isoAsp deriva-
tives in higher amount. Among the new cyclic NGR
peptide–daunomycin conjugates the most effective compound
was Dau=Aoa-GFLGK(c[NleNGRE]-GG)-NH2, which showed
similar activity against HT-1080 CD13+ cells to Dau=Aoa-
GFLGK(c[KNGRE]-GG)-NH2, and a significantly higher anti-
tumor effect against HT-29 CD13− but integrin receptor posi-
tive cells. This might be explained by the binding affinity of
isoDGR peptides to integrin receptors. However, to confirm this
findings further binding studies of cyclic NGR peptide–drug
conjugates to different integrin receptors are needed. Taken
together, the synthetic and biological results suggest that the
Dau=Aoa-GFLGK(c[NleNGRE]-GG)-NH2 conjugate is more
suitable for drug targeting with dual acting propensity than our
control lead compound.
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Experimental
Synthesis of the novel peptide–drug conju-
gates
Linear precursor peptides were prepared on Rink-Amide
MBHA resin by SPPS. Standard Fmoc protected amino acids
(Iris Biotech GmbH, Marktredwitz, Germany) were used for the
synthesis except Fmoc-Lys(Mtt)-OH that was applied for the
development of branching in the peptide. The protocol of the
SPPS was similarly as described in [17] as follows: (i) DMF
washing (4 × 0.5 min), (ii) Fmoc deprotection with 2% DBU,
2% piperidine, 0.1 M HOBt in DMF (4 times; 2 + 2 + 5 +
10 min), (iii) DMF washing (10 × 0.5 min), (iv) coupling of
Fmoc-protected amino acid derivative: DIC:HOBt in DMF
(4 equiv each) (1 × 60 min), (v) DMF washing (3 × 0.5 min),
(vi) DCM washing (2 × 0.5 min), (vii) ninhydrin or isatin test.
The cleavage of Mtt protecting group was achieved by using
2% TFA in DCM for 6 × 4 min. The coupling of the isopropyli-
dene protected aminooxyacetic acid [17] to the N-terminus
of the linker sequence was carried out by using standard
protocol DIC/HOBt coupling. The cleavage from the solid
support was performed at rt in a solution of 95% TFA, 2.5%
triisopropylsilane, and 2.5% water for 3 h. The resin
was then filtered and the crude product was precipitated with
cold diethyl ether and pellet centrifugated for 5 min at
4000 rpm. After washing (3 times with ether) the remaining
pellet was dissolved in water and lyophilized. The lyophilized
compound was then purified by RP-HPLC prior to the cycliza-
tion.
Cyclization
Prior to the head-to-side chain cyclization a salt exchange needs
to be performed using 10 equiv of pyridinium hydrochloride in
5 mL MeOH. After 20 min volatiles were removed under
reduced pressure, the remaining oily compound was dissolved
in dry DMF at a concentration of 0.5 mg/mL. The pH of the
solution was adjusted to pH 8 with DIPEA, then BOP and
HOBt (3 equiv each) are added to the mixture. The reaction was
followed by analytical HPLC till the complete conversion. At
the end DMF was removed and the oily compound was dis-
solved in acetonitrile–water and purified by RP-HPLC and the
collected fractions lyophilized.
Purification
Analogous to the description in [17] RP-HPLC purification was
used for the isolation of pure peptides and conjugates. A
KNAUER 2501 HPLC system (KNAUER, Bad Homburg,
Germany) was applied with a semi-preparative Phenomenex
Luna C18 column (250 mm × 21.2 mm) with 10 µm silica
(100 Å pore size) (Torrance, CA). Linear gradient elution
(0 min 15% B; 5 min 15% B; 55 min 70% B) with eluent A
(0.1% TFA in water) and eluent B (0.1% TFA in MeCN–H2O
(80:20, v/v)) was used at a flow rate 9.5 mL/min. Peaks were
detected at 220 nm.
Chemostability studies
As described in [17] to check the chemical stability each of the
drug conjugates were dissolved in DMSO (2% of the final
volume), following the addition of 10% FBS (fetal bovine
serum) containing complete cell culture medium (DMEM CM)
up to the 1 mg/mL final concentration. Each conjugate was
allowed to incubate at 37 °C. Samples were analyzed at experi-
ment time of 0 h, 6 h and 72 h, respectively, and components
were purified with Amicon Ultra Centrifugal Filters (cut off
10K Millipore). The membranes were washed with eluent A
(HPLC), followed by 3 × 15 min centrifugation at 13000 rpm.
The last step is the washing with eluent B (HPLC) 1 × 15 min,
followed by lyophilization and concentration of the samples.
In vitro cytostatic effect and cytotoxicity
HT-1080 was maintained in DMEM while HT-29 cells in RPMI
(Sigma-Aldrich), respectively, supplemented with 10% FBS,
5 mmol/L glutamine, and 50 units/mL penicillin and strepto-
mycin (Life Technologies). As described in [17] cells were
seeded in 5000 cells/well density in 100 μL medium followed
by an overnight incubation. The next day 100 μL of serially
diluted drugs were added to the cells. For the measurements of
cytostatic effect, drug containing medium was gently removed
from the plates after 6 h incubation, fresh medium was added to
each wells, and the plates were further incubated for additional
66 h (72 h in total). In the case of cytotoxicity measurements,
the drug containing medium was on the cells for the full period
of the 72 h assay. At 72 h, supernatant was removed from the
cells, and viability was assessed by the PrestoBlue® reagent
(Life Technologies), which was diluted in PBS to reach the con-
centration given in the manufacturer’s instruction.
Lysosomal degradation
Rat liver lysosomal homogenate was prepared for this experi-
ment. The protein concentration was detected with bicin-
choninic acid (Pierce BCA protein assay) following the manu-
facturer’s protocol (ThermoFischer Scientific, Rockford, IL,
USA), and it was 17.4 μg/µL. The peptide–drug conjugates
were dissolved in deionized water (4 μg/mL concentration). The
solutions were further diluted to a concentration of 0.2 μg/µL
using 0.2 M of NH4OAc (pH 5.0). The lysosomal homogenate
was diluted with 0.2 M NH4OAc (pH 5.0) to a concentration of
3.48 µg/µL. The homogenate was then added to the conjugates
in a ratio of 1:1 w/w. All the degradation mixtures were kept at
37 °C, samples of 13 µL were taken at 0 h, 6 h and 72 h. Reac-
tion mixtures were quenched by the addition of 2 µL of formic
acid. LC–MS analysis was performed at the end on each sam-
ple.
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Cell uptake
Analogous to the description in [17], prior to the treatment,
HT-1080 and HT-29 cells were incubated overnight in cell
culture medium (see above) followed by seeding at a
250.000 cells/well density. Peptide–drug conjugates were dis-
solved in FBS containing cell culture medium and added to the
cells at 10 μM final concentration. After 6 h incubation at 37 °C
the supernatant was removed, cells were washed with PBS and
trypsinised with 0.1% trypsin (Gibco® by Life Technologies)
for 10 minutes. Trypsinization was terminated with FBS con-
taining medium, then cells were washed and suspended in
serum free medium. For live/dead detection we used Zombie
Violet reagent (Biolegend, San Diego CA). Samples were
detected and analyzed by using an Attitude® Acoustic Focusing
Cytometer (ThermoFischer Scientific).
Supporting Information
Supporting Information File 1
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